FOSCARNET SODIUM

Post-LOE

foscarnet sodium

Pfizer

ANDAINTRAVENOUSSOLUTION

Approved

May 2005

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

FOSCARNET SODIUM (foscarnet sodium) by Pfizer is mechanism of action foscarnet exerts its antiviral activity by a selective inhibition at the pyrophosphate binding site on virus-specific dna polymerases at concentrations that do not affect cellular dna polymerases. Approved for cmv retinitis in patients with acquired immunodeficiency syndrome (aids), acyclovir-resistant mucocutaneous hsv infections in immunocompromised patients. First approved in 2005.

Drug data last refreshed 19h ago

Mechanism of Action

Mechanism of Action Foscarnet exerts its antiviral activity by a selective inhibition at the pyrophosphate binding site on virus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases. Foscarnet does not require activation (phosphorylation) by thymidine kinase or…

Indications (2)

CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS)acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients

Worked on FOSCARNET SODIUM at Pfizer? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.